Prelude Therapeutics (PRLD) Common Equity (2019 - 2026)

Prelude Therapeutics (PRLD) has 8 years of Common Equity data on file, last reported at $60.2 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 41.67% year-over-year to $60.2 million; the trailing twelve-month figure through Mar 2026 stood at $60.2 million (down 41.67% YoY), and the FY2025 full-year result was $68.6 million, down 47.79% from the prior year.
• Common Equity declined to $60.2 million in Q1 2026, from $68.6 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $262.1 million in Q2 2023 to a low of $58.5 million in Q3 2025.
• A 5-year average of $169.1 million and a median of $182.3 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity gained 21.31% in 2023 and slumped 62.58% in 2025, its largest moves.
• Tracing PRLD's Common Equity over 5 years: stood at $195.4 million in 2022, then increased by 21.31% to $237.1 million in 2023, then plunged by 44.55% to $131.5 million in 2024, then plunged by 47.79% to $68.6 million in 2025, then decreased by 12.32% to $60.2 million in 2026.
• Business Quant data shows PRLD's Common Equity at $60.2 million in Q1 2026, $68.6 million in Q4 2025, and $58.5 million in Q3 2025.